TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Taysha Gene Therapies Inc (TSHA) is not a strong buy at this moment for a beginner investor with a long-term focus. While there are positive catalysts such as hedge fund buying and favorable analyst ratings, the lack of recent news, poor financial performance, and no strong trading signals suggest holding off on investment until more favorable conditions arise.
The MACD is positive and expanding, indicating a potential upward trend. RSI is neutral at 52.75, and moving averages are converging, suggesting no clear directional momentum. The stock is trading near its pivot point of 4.603, with resistance at 4.792 and support at 4.414.
Hedge fund buying has increased significantly by 649.63% in the last quarter. Analysts have raised price targets and remain optimistic about the company's potential in Rett syndrome studies.
The company's financial performance is weak, with revenue dropping to zero and EPS declining. No recent news or significant insider trading activity is available. Congress trading data is also absent. Stock trend analysis indicates a higher probability of short-term declines.
In Q3 2025, revenue dropped to 0 (-100% YoY), net income improved to -$32.73M (+28.24% YoY), EPS declined to -0.09 (-10% YoY), and gross margin remained at 100%.
Analysts are optimistic, with multiple firms raising price targets to $11-$19 and maintaining Overweight or Buy ratings. The focus is on the company's potential success in Rett syndrome studies.
